This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
Clinical Insider

Massive Bio teams with AI genomics firm Inocras with eye on cancer trial recruitment

Posted by on 10 June 2024
Share this article

Massive Bio and Inocras have teamed up to add genome sequencing and bioinformatics to its clinical trial matching offering.

The partnership – announced at the ASCO annual meeting – will combine Inocras’ AI-driven whole genome sequencing tech with Massive Bio’s matching system – which also relies on AI – in a bid to help more people with cancer take part in clinical trials.

In addition, patients who consent to genome sequencing will be informed of future clinical trials without the need for additional genetic tests according to the firms.

Massive Bio CFO, Toygun Onaran, said “We are setting a new standard in cancer care, emphasizing a data-driven and patient-centric approach by harnessing the power of AI and cutting-edge genomic testing to increase access for cancer patients benefiting from precision medicine.”

Rebecca Jang, chief of strategy officer at Inocras, framed the partnership as a mechanism for facilitating access to healthcare.

“Not all patients have available treatment options matched with their biomarkers. For them, clinical trials are their next hope…Our robust biomarker data will be further enriched by Massive Bio's capabilities, facilitating more precise patient matching with effective clinical trials.”

Cancer deals

Massive Bio’s core technology is Synergy-AI, a platform it claims can analyse and summarize medical records, including biomarker data from multiple sources, to match patients with the over 14,000 clinical trials currently on its books.

The agreement is Massive Bio’s third cancer-focused accord in a year following its agreement with the Precision Cancer Consortium.

More recently, the firm expanded a partnership with Un Ensayo Para Mi (UEPM), a clinical trial search platform, to enhance access to oncology clinical trials in select regions in Latin America.

And for Inocras- which was previously known as Genome Insight - the deal comes just weeks after the formation of a partnership with IMBdx, a specialist provider of liquid biopsy-based diagnostics for cancer research and diagnosis.


Share this article

Sign up for Clinical Insider email updates